BACKGROUND: @entity1149 ( @entity1149 )- @entity1 treated with standard chemotherapy experienced progression rapidly. A novel therapy based on programed death 1 ( @entity8395 )/programed death ligand 1 ( @entity4634 ) inhibitors showed an increasing potential in several @entity5 including advanced @entity1149 . OBJECTIVES: This article is a meta-analysis aiming to systematically evaluate the efficacy and safety profiles of @entity8395 / @entity4634 agents in @entity1 with @entity1149 . DATA SOURCES: Data were collected from eligible studies searched from PubMed, ScienceDirect, and Web of Science. SYNTHESIS METHODS: Pooled hazard ratio (HR) for @entity1349 ( @entity1349 ) and progression-free survival (PFS) was estimated to assess the efficacy of @entity8395 / @entity4634 inhibitors versus @entity1205 , pooled odds ratio (OR) was calculated for objective response rate (ORR). The overall frequency was estimated for 1-year @entity1349 , 1-year progression-free survival, and ORR. A subgroup analysis among @entity1149 @entity1 tested with different @entity470 ( @entity470 ) status was also performed to figure out the relationship between @entity470 status and efficacy of @entity8395 / @entity4634 therapies. OR for occurrence of any grade and grade 3 to 5 treatment-related adverse effect was calculated for evaluating the safety of @entity8395 / @entity4634 therapies. RESULTS: Nine studies were included in this analysis. The pooled HRs for @entity1349 and PFS were 0.68 (95% confidence interval [CI] 0.61-0.75) and 0.83 (95% CI 0.75-0.91), respectively, the pooled OR for ORR was 1.83 (95% CI 1.41-2.36), indicating a significant improvement in @entity1349 , PFS, and ORR. In the results of subgroup analysis, the HR for @entity1349 in @entity1149 @entity1 was 1.05 (95% CI 0.69-1.59) in @entity1 with mutant @entity470 and 0.66 (95% CI 0.57-0.77) in @entity1 with wild-type @entity470 status. OR for occurrence was 0.36 (95% CI 0.28-0.46) in any grade treatment-related adverse effect and 0.18 (95% CI 0.14-0.22) in grade 3 to 5 treatment-related adverse effect, suggesting a superior safety profile of @entity8395 / @entity4634 inhibitors. CONCLUSION: The @entity8395 / @entity4634 therapy significantly prolonged the @entity1349 and improved the ORR, simultaneously lowering the treatment-related adverse effect events versus @entity1205 .

A meta-analysis of efficacy and safety of antibodies targeting @entity8395 / XXXX in treatment of advanced @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4634 :: ('29126', 'Gene') :: ['PD-L1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Nonsmall cell lung cancer'] @entity8395 :: ('5133', 'Gene') :: ['PD-1'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity4634 :: (29126,Gene) :: ['PD-L1']
